UAS regulatory sequences drive expression of an arctic variant (E22G) Aβ1-42 peptide.
This construct carries the amyloid Aβ42 peptide; variant described relative to the full-length protein and in terms of the Aβ42 peptide.
Flies expressing Hsap\APParctic.Aβ42.Scer\UAS.att under the control of Scer\GAL4elav-C155 exhibit significantly reduced rhythmicity in constant darkness (DD) compared to controls. The phenotype is from 2-12 days after eclosion onwards and progresses with increased age. Overall locomotor activity is unaffected. The flies exhibit the anticipatory ramping seen in control flies 2-3 hours prior to dusk or dawn in 12 hour light:dark conditions (LD). However, while control flies retain robust circadian behaviour when shifted to constant darkness (DD), the mutant flies become arrhythmic and are unable to re-synchronise within 24 hours of being shifted back to LD. A significantly reduced lifespan is seen compared to controls and, as in controls, lifespan is shorter in constant light conditions (LL) compared with LD. No loss of the LNv and ILNv clock neurons or the dorsal neuron groups LNd and DN1 is observed. Locomotor rhythm in DD is comparable to controls when Hsap\APParctic.Aβ42.Scer\UAS.att is expressed under the control of either Scer\GAL4tim.PE or Scer\GAL4P2.4.Pdf.
Median survival of flies expressing Scer\GAL4elav-C155>Hsap\APParctic.Aβ42.Scer\UAS.att is 31 days compared with 66 days in control flies.
Expression of Hsap\APParctic.Aβ42.Scer\UAS.att under the control of Scer\GAL4elav-C155 results in the proliferation of AΒ plaques throughout the fly brain.
Expression of Hsap\APPArctic.Aβ42.Scer\UAS.cJa.T:SS-nec under the control of Scer\GAL4elav-C155 results in the proliferation of AΒ plaques throughout the fly brain. These individuals display significant decreases in adul locomotion and in adult lifespan, as compared to controls.
Flies expressing Scer\GAL4elav-C155>Hsap\APParctic.Aβ42.Scer\UAS.att become significantly and progressively impaired in their climbing ability. After day 10 the mutant flies are no longer able to climb the sides of the test tubes.
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has short lived phenotype, non-enhanceable by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal neuroanatomy phenotype, non-enhanceable by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal locomotor behavior phenotype, non-enhanceable by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has short lived phenotype, suppressible by PsaUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal neuroanatomy phenotype, suppressible by PsaUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal locomotor behavior phenotype, suppressible by PsaUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has short lived phenotype, non-suppressible by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal neuroanatomy phenotype, non-suppressible by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has abnormal locomotor behavior phenotype, non-suppressible by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has adult brain phenotype, non-enhanceable by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has eye phenotype, non-enhanceable by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has adult brain phenotype, suppressible by PsaUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has eye phenotype, suppressible by PsaUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has adult brain phenotype, non-suppressible by cueUAS.cKa, Scer\GAL4elav-C155
Hsap\APPArctic.Aβ42.UAS.cJa.Tag:SS(nec), Scer\GAL4elav-C155 has eye phenotype, non-suppressible by cueUAS.cKa, Scer\GAL4elav-C155
Overexpression of CG14715G6908 in Scer\GAL4elav-C155>Hsap\APParctic.Aβ42.Scer\UAS.att flies results in a significant increase in climbing ability in early adulthood but has no effect on survival.
Co-expression of CG14715GD4788 with Hsap\APParctic.Aβ42.Scer\UAS.att using Scer\GAL4elav-C155 results in a significant increase in survival, but no improvement in climbing ability.
Co-expression of CG14715KK104150 with Hsap\APParctic.Aβ42.Scer\UAS.att using Scer\GAL4elav-C155 results in a significant increase in survival, but no improvement in climbing ability.
Co-expression of PGRP-SC1bGD5490 using Scer\GAL4elav-C155 ameliorates the Hsap\APParctic.Aβ42.Scer\UAS.att phenotypes: the flies show improved climbing and survival.
Co-expression of Sod3GD4801 using Scer\GAL4elav-C155 ameliorates the Hsap\APParctic.Aβ42.Scer\UAS.att phenotypes: the flies show improved climbing and survival.
Co-expression of PsaScer\UAS.cKa results in an increase in median survival in flies expressing Hsap\APParctic.Aβ42.Scer\UAS.att under the control of Scer\GAL4elav-C155. In addition, PsaScer\UAS.cKa expression suppresses the retinal toxicity associated with Hsap\APParctic.Aβ42.Scer\UAS.att expression, resulting in normal eye development. These flies are also functionally protected, as shown by improved locomotor function throughout their adult life, as compared to flies expressing Hsap\APParctic.Aβ42.Scer\UAS.att alone. Coexpression of PsaScer\UAS.cKa results in a marked reduction in the number of AΒ deposits.
Co-expression of cueScer\UAS.cKa does not affect the toxicity associated with expression of Hsap\APParctic.Aβ42.Scer\UAS.att under the control of Scer\GAL4elav-C155.